Paeds Vivas · mental-behavioural-and-psychosomatic
Early-onset psychosis and mania — branching viva
Branching viva on the psychosis-mania gate: distinguishing psychosis, mania and mimics, organic exclusion, duration of untreated psychosis, cannabis risk, TEOSS and the paediatric mania trials, and antipsychotic metabolic monitoring.
On this page & tools
Target exams
Opening
Examiner: A 15-year-old boy is brought in believing classmates implanted a chip in his head, has not slept for four nights, and smokes high-potency cannabis daily. Walk me through your approach from the moment you meet him. [2]
Candidate: He is a medical patient first and a psychiatric patient second. I run the gate in order: assess, distinguish, exclude danger, refer early and treat. I greet him first, set a joint agenda, and secure time alone with conditional confidentiality stated aloud. Because a psychotic young person is an unreliable sole historian, I gather collateral from family and school on onset, course, function, family psychiatric history, substance use and trauma. I perform a mental-state examination, run HEEADSSS with focused probes, and screen suicide risk with plan, intent and means — then exclude organic disease before any label. [2]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References9Show ledgerHide ledger
- [1]Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry, 2008.PMID 18794207
- [2]McClellan J, Stock S Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2013.PMID 23972700
- [3]Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry, 2008.PMID 18180426
- [4]Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 2014.PMID 25252316
- [5]Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007.PMID 17662880
- [6]Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 2002.PMID 12446537
- [7]Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of General Psychiatry, 2012.PMID 22213771
- [8]Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry, 2006.PMID 16816222
- [9]Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry, 2007.PMID 17898346